{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:06:02Z","timestamp":1793747162469,"version":"4.6.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Polycystic ovary syndrome (PCOS) occurs in approximately 10% of all reproductive\u2010age women, with over 50% of these patients having imaging\u2010confirmed nonalcoholic fatty liver disease (NAFLD). Whether PCOS increases the risk for more clinically relevant disease, such as nonalcoholic steatohepatitis (NASH), is unclear. Such findings are relevant to prognosticating risk of progressive liver disease in the growing population of young adults with NAFLD. Using weighted discharge data from the United States National Inpatient Sample from 2016 to 2018, we evaluated the association of PCOS with the presence of NASH among reproductive\u2010age women with NAFLD. The association of PCOS with NASH was assessed by logistic regression, adjusting for demographic and comprehensive metabolic comorbidities. Other causes of hepatic steatosis and chronic liver diseases were excluded. Our analysis included 189,440 reproductive\u2010age women with NAFLD, 9415 of whom had PCOS. Of those with PCOS, 1390 (15%) had a distinct code for NASH. Women with PCOS were younger (median age, 33 vs. 40\u2009years;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u00a0&lt;\u20090.001) and more likely to have diabetes (37.0% vs. 34.0%), obesity (83.0% vs. 58.0%), dyslipidemia (26.0% vs. 21.0%), and hypertension (38.0% vs. 35.0%) (all\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u00a0\u2264\u20090.01). On adjusted analysis accounting for these metabolic comorbidities, PCOS remained independently associated with an increased prevalence of NASH (adjusted odds ratio, 1.22; 95% confidence interval, 1.05\u20131.42;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u00a0=\u20090.008).\n                    <jats:italic toggle=\"yes\">Conclusions<\/jats:italic>\n                    : Among reproductive\u2010age women with NAFLD, metabolic risk factors were more common in those with PCOS. Despite adjustment for these metabolic comorbidities, PCOS remained associated with a 22% higher odds of having NASH. These findings support efforts to increase NAFLD screening in young women with PCOS and highlight the potential \u201chead start\u201d in progressive liver disease among young women with PCOS.\n                  <\/jats:p>","DOI":"10.1002\/hep4.2039","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T09:05:12Z","timestamp":1658394312000},"page":"2634-2639","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age"],"prefix":"10.1097","volume":"6","author":[{"given":"Stephanie S.","family":"Maldonado","sequence":"first","affiliation":[{"name":"Department of Medicine,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Grab","sequence":"additional","affiliation":[{"name":"The Liver Center,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie W.","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Huddleston","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Cedars","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sarkar","sequence":"additional","affiliation":[{"name":"The Liver Center,University of California San Francisco,San Francisco,California,USA"},{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Francisco,San Francisco,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"6","key":"hep42039-bib-0001-20241127","first-page":"336","article-title":"Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches","volume":"38","year":"2013","journal-title":"P T"},{"issue":"2","key":"hep42039-bib-0002-20241127","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"4","key":"hep42039-bib-0003-20241127","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11901-019-00495-9","article-title":"NAFLD in women: unique pathways, biomarkers and therapeutic opportunities","volume":"18","year":"2019","journal-title":"Curr Hepatol Rep"},{"issue":"10","key":"hep42039-bib-0004-20241127","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2012-1382","article-title":"Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"hep42039-bib-0005-20241127","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.cgh.2020.09.045","article-title":"Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"hep42039-bib-0007-20241127","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"hep42039-bib-0008-20241127","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","year":"2021","journal-title":"J Clin Endocrinol Metabol"},{"issue":"6","key":"hep42039-bib-0009-20241127","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"hep42039-bib-0010-20241127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"hep42039-bib-0011-20241127","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/hep.29068","article-title":"Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic","volume":"65","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"hep42039-bib-0012-20241127","article-title":"Increasing prevalence of NAFLD\/NASH among children, adolescents and young adults from 1990 to 2017: a population\u2010based observational study","volume":"11","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"hep42039-bib-0013-20241127","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/AOG.0000000000002656","article-title":"ACOG Practice Bulletin No. 194: polycystic ovary syndrome","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"1","key":"hep42039-bib-0014-20241127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1017\/S0954422416000287","article-title":"Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges","volume":"30","year":"2017","journal-title":"Nutr Res Rev"},{"issue":"4","key":"hep42039-bib-0015-20241127","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2468-1253(21)00055-8","article-title":"Relevance of reproductive health to comprehensive hepatology care","volume":"6","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"hep42039-bib-0016-20241127","first-page":"1429","article-title":"Twenty\u2010four\u2010hour mean plasma testosterone concentration declines with age in normal premenopausal women","volume":"80","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"hep42039-bib-0017-20241127","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jhep.2014.11.002","article-title":"Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity","volume":"62","year":"2015","journal-title":"J Hepatol"},{"issue":"9","key":"hep42039-bib-0018-20241127","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2017-00947","article-title":"AKR1C3\u2010mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"hep42039-bib-0019-20241127","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"International PCOS Network. Recommendations from the international evidence\u2010based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","year":"2018","journal-title":"Fertil Steril"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2039","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2039","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T07:13:50Z","timestamp":1732691630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2039","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"2022-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}